The emerging prevalence for biohacking peptides has created a significant grey market, posing both intriguing possibilities and considerable risks. These unlicensed products, often procured from international manufacturers, bypass established pharmaceutical routes, allowing purchase at discounted prices. However, the lack of quality assurance and s